ZA200802512B - Stem cell fusion model of carcinogenesis - Google Patents

Stem cell fusion model of carcinogenesis

Info

Publication number
ZA200802512B
ZA200802512B ZA200802512A ZA200802512A ZA200802512B ZA 200802512 B ZA200802512 B ZA 200802512B ZA 200802512 A ZA200802512 A ZA 200802512A ZA 200802512 A ZA200802512 A ZA 200802512A ZA 200802512 B ZA200802512 B ZA 200802512B
Authority
ZA
South Africa
Prior art keywords
carcinogenesis
stem cell
cell fusion
fusion model
model
Prior art date
Application number
ZA200802512A
Other languages
English (en)
Inventor
David T Harris
Tom C Tsang
He Xianghui
Brian L Pipes
Linda C Meade-Tollin
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of ZA200802512B publication Critical patent/ZA200802512B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200802512A 2005-08-25 2008-03-14 Stem cell fusion model of carcinogenesis ZA200802512B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71124905P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
ZA200802512B true ZA200802512B (en) 2009-01-28

Family

ID=37772481

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802512A ZA200802512B (en) 2005-08-25 2008-03-14 Stem cell fusion model of carcinogenesis

Country Status (16)

Country Link
US (2) US8158126B2 (xx)
EP (2) EP2363146B1 (xx)
JP (2) JP5400381B2 (xx)
KR (2) KR101413055B1 (xx)
CN (2) CN103212071B (xx)
AU (2) AU2006282853B2 (xx)
BR (1) BRPI0615081A2 (xx)
CA (2) CA2620616C (xx)
ES (2) ES2523857T3 (xx)
HK (1) HK1161976A1 (xx)
HU (1) HUE025948T2 (xx)
IL (2) IL189674A (xx)
RU (1) RU2404805C2 (xx)
SG (1) SG152229A1 (xx)
WO (1) WO2007025216A2 (xx)
ZA (1) ZA200802512B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4216700A (en) 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
CN103212071B (zh) * 2005-08-25 2017-12-12 亚利桑那大学董事会 干细胞融合癌发生模型
US20120295344A1 (en) * 2006-08-25 2012-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem Cell Fusion Model of Carcinogenesis
WO2007035718A2 (en) 2005-09-19 2007-03-29 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
EP1973948B1 (en) 2005-12-15 2015-02-11 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP2247617B1 (en) 2008-01-18 2013-02-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
CN101760452B (zh) * 2008-11-18 2012-12-19 中国科学院上海生命科学研究院 一种胚胎干细胞和肿瘤细胞的杂合细胞系及其构建方法
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
AU2011339929B2 (en) 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
US9321844B2 (en) 2011-08-05 2016-04-26 Genentech, Inc. Anti-polyubiquitin antibodies
CN110391025A (zh) * 2018-04-19 2019-10-29 清华大学 一种面向宏微观多维度胃癌早期风险评估的人工智能建模方法
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007321A2 (en) * 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
US6007816A (en) * 1989-03-17 1999-12-28 Fred Hutchinson Cancer Research Center Methods of using CD44-specific antibodies
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
US6007819A (en) 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
JP2004507459A (ja) * 1999-08-25 2004-03-11 アルタレックス　コーポレイション 免疫病態治療用組成物および方法
CA2522727A1 (en) 2003-04-18 2004-11-04 University Of Massachusetts Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer
CN1302102C (zh) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途
US20060033366A1 (en) 2004-08-11 2006-02-16 Jeffrey Vernon M Headrest display device
CN101583273A (zh) * 2005-07-22 2009-11-18 加利福尼亚大学董事会 肝素组合物和选择素抑制
CN103212071B (zh) * 2005-08-25 2017-12-12 亚利桑那大学董事会 干细胞融合癌发生模型

Also Published As

Publication number Publication date
CA2620616C (en) 2016-06-14
AU2011201605A1 (en) 2011-04-28
JP2009505664A (ja) 2009-02-12
US8758755B2 (en) 2014-06-24
RU2008111144A (ru) 2009-09-27
KR20080048499A (ko) 2008-06-02
EP1924685B1 (en) 2014-08-27
AU2011201605B2 (en) 2012-12-20
HUE025948T2 (en) 2016-05-30
CA2808168C (en) 2018-06-12
ES2523857T3 (es) 2014-12-02
JP5597171B2 (ja) 2014-10-01
AU2006282853B2 (en) 2011-01-20
CA2808168A1 (en) 2007-03-01
JP2011225613A (ja) 2011-11-10
WO2007025216A3 (en) 2007-07-05
US20090016961A1 (en) 2009-01-15
EP2363146A1 (en) 2011-09-07
RU2404805C2 (ru) 2010-11-27
IL222468A (en) 2015-10-29
CN103212071B (zh) 2017-12-12
SG152229A1 (en) 2009-05-29
CN103212071A (zh) 2013-07-24
EP1924685A4 (en) 2009-03-04
US20120201808A1 (en) 2012-08-09
WO2007025216A2 (en) 2007-03-01
ES2552101T3 (es) 2015-11-25
CA2620616A1 (en) 2007-03-01
BRPI0615081A2 (pt) 2011-05-03
JP5400381B2 (ja) 2014-01-29
AU2006282853A1 (en) 2007-03-01
KR101413048B1 (ko) 2014-06-30
EP2363146B1 (en) 2015-06-24
EP1924685A2 (en) 2008-05-28
IL189674A (en) 2012-10-31
CN101273124A (zh) 2008-09-24
CN101273124B (zh) 2013-05-08
IL189674A0 (en) 2008-06-05
US8158126B2 (en) 2012-04-17
KR20130020738A (ko) 2013-02-27
KR101413055B1 (ko) 2014-07-02
HK1161976A1 (en) 2012-08-17

Similar Documents

Publication Publication Date Title
IL189674A0 (en) Stem cell fusion model of carcinogenesis
HK1225753A1 (zh) 使用胎盤幹細胞的免疫調節
GB2441530B (en) Stem Cells
HK1219295A1 (zh) 衍生胚胎幹細胞
GB2432835B (en) Culturing human embryonic stem cells
EP1809740A4 (en) CARDIAC STEM CELLS
GB0709533D0 (en) Platelets from stem cells
AU308501S (en) Earplug stem
EP2007411A4 (en) REGULATORY STEM CELLS
GB0505064D0 (en) Production of bio-diesel
EP1838724A4 (en) STEM CELL FACTOR PROTEINS AND USES THEREOF
EP1917348A4 (en) ISOLATION OF MULTIPLE LINE STEM CELLS
GB0624554D0 (en) Model Calibration
GB2425129B (en) Cytotrophoblast stem cell
EP2009094A4 (en) FUSION PARTNER CELLS
ZA200803930B (en) Immunomodulation using placental stem cells
GB0507983D0 (en) Apoptosis model
GB0511723D0 (en) Placental stem cells
GB0515305D0 (en) Stem cell markers 1
GB0500869D0 (en) Stem cells
GB0412861D0 (en) Screening of stem cells
GB0410910D0 (en) Stem cells
GB0403074D0 (en) Stem cells
AU2006900111A0 (en) Human embryonic stem cell clones
GB0625041D0 (en) Prostate stem cell model